Dr Sara Mohamed
Conjoint Associate Lecturer

Dr Sara Mohamed

2022            PhD (Paediatric Leukaemia), Faculty of Medicine and Health, University of New South Wales, Australia
2016            MSc (Drug Technology), Faculty of Pharmacy, Ain Shams University, Egypt
2008            BSc (Pharmaceutical Sciences), Faculty of Pharmacy, Ain Shams University, Egypt

Medicine & Health
School of Clinical Medicine

A biomedical scientist and self-motivated researcher with over 10 years of experience in drug delivery systems, with unique and multidisciplinary skills combined with a passion to see my research, make a difference in people’s lives. I joined the Children’s Cancer Institute, UNSW in July 2018 to conduct my PhD studies on developing innovative therapeutics for the treatment of one of the high-risk haematologic malignancies in children and adults: Philadelphia-chromosome like Acute Lymphoblastic leukaemia (Ph-ALL). 

Before joining the Institute, I worked as a Researcher and Assistant Lecturer at the Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University in Egypt, where my research focused on the development and evaluation of innovative nanoparticles to improve the skin delivery of drugs. Here, I developed expertise in several cutting-edge knowledge in nanotechnology and received a master’s degree in Drug Technology.

To date, my research has been internationally recognised as first-author peer-reviewed publications in high-impact journals such as the International Journal of Biological Macromolecules. I have also given multiple international presentations at world-class conferences, including the American Society of Haematology. I am also partnering with the UNSW by holding an appointment as a Conjoint Associate Lecturer in the School of Clinical Medicine, Faculty of Medicine at UNSW Sydney. 

Location
Children's Cancer Institute Lowy Cancer Research Centre, UNSW Australia PO Box 81 Randwick 2031 Australia
  • Book Chapters | 2020
    Abdel Samie SM; Nasr M, 2020, 'Food to medicine transformation of stilbenoid vesicular and lipid-based nanocarriers: Technological advances', in Drug Delivery Aspects, Elsevier, pp. 227 - 245, http://dx.doi.org/10.1016/b978-0-12-821222-6.00011-7
  • Journal articles | 2021
    Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB, 2021, 'A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia', International Journal of Biological Macromolecules, 190, pp. 214 - 223, http://dx.doi.org/10.1016/j.ijbiomac.2021.08.194
    Journal articles | 2016
    AbdelSamie SM; Kamel AO; Sammour OA; Ibrahim SM, 2016, 'Terbinafine hydrochloride nanovesicular gel: In vitro characterization, ex vivo permeation and clinical investigation.', Eur J Pharm Sci, 88, pp. 91 - 100, http://dx.doi.org/10.1016/j.ejps.2016.04.004
  • Conference Abstracts | 2020
    Mohamed SMA; Sia K; Friedrich K-H; Wohlmann A; Savvides S; Schofield P; Christ D; Kavallaris M; Lock RB; Bayat N, 2020, 'A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-138421

2018 -2022            University International Postgraduate Award (UIPA), UNSW 
2018-2022             Children’s Cancer Institute Postgraduate Supplementary Scholarship
2019                      Kids Cancer Alliance (KCA) PhD Top-Up Scholarship 2019
2021                      Translational Cancer Research Network PhD Top-Up Scholarship (TCRN) 

With my multidisciplinary expertise in Nanotechnology, Drug Delivery, Precision Medicine and Experimental Therapeutics, my research focus is the translational development of innovative therapeutics for the treatment of high-risk diseases and leukaemia. I am currently expanding my research horizon to improve treatment outcomes of high-risk acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL). These projects will address the unmet therapeutic needs of high-risk leukaemia and have the potential to bring relief to hundreds of leukaemia patients in Australia and many more around the globe.